Solana

Solana ROIC

The Return on Invested Capital (ROIC) of Solana (HSDT) as of Oct 21, 2026 is -13.59 %. In the previous year, Return on Invested Capital (ROIC) was -1,096.36 % — a change of -98.76% (higher).

ROIC

-13.59 %

YoY

-98.76%

Last updated:

Return on Invested Capital (ROIC) of Solana is 2025 -13.59 % . Return on Invested Capital (ROIC) of Solana was 2024 -1,096.36 % . It decreases by -98.76% higher compared to the previous year.

The Solana ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
-121.17 USD
Jan 1, 2019
-151.13 USD
Jan 1, 2020
-356.64 USD
Jan 1, 2021
-161.04 USD
Jan 1, 2022
-170.34 USD
Jan 1, 2023
-367.68 USD
Jan 1, 2024
-1,096.36 USD
Jan 1, 2025
-13.59 USD
The Solana ROIC history
YEARROICYoY
-13.59 %-98.76%
-1,096.36 %+198.18%
-367.68 %+115.85%
-170.34 %+5.77%
-161.04 %-54.84%
-356.64 %+135.98%
-151.13 %+24.73%
-121.17 %-128.02%
432.40 %-380.10%
-154.38 %-61.65%
-402.55 %-99.24%
-53,056.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solana stock

Return on Invested Capital (ROIC) of Solana is -13.59 % in 2025.

Return on Invested Capital (ROIC) of Solana changed from -1,096.36 % to -13.59 %, representing a -98.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Solana since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Solana with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Solana

All Key Metrics — Solana